ErysotramidineCAS# 52358-58-4 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 52358-58-4 | SDF | Download SDF |
PubChem ID | 11034782 | Appearance | Oil |
Formula | C19H21NO4 | M.Wt | 327.4 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R,13bS)-2,11,12-trimethoxy-1,2,8,9-tetrahydroindolo[7a,1-a]isoquinolin-6-one | ||
SMILES | COC1CC23C(=CC(=O)N2CCC4=CC(=C(C=C34)OC)OC)C=C1 | ||
Standard InChIKey | AUDDBHVKKYSXKU-LIRRHRJNSA-N | ||
Standard InChI | InChI=1S/C19H21NO4/c1-22-14-5-4-13-9-18(21)20-7-6-12-8-16(23-2)17(24-3)10-15(12)19(13,20)11-14/h4-5,8-10,14H,6-7,11H2,1-3H3/t14-,19-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. (+)-Erysotramidine shows potent dosedependant antifeedant activity at concentrations 3100 ppm. |
Erysotramidine Dilution Calculator
Erysotramidine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0544 mL | 15.2718 mL | 30.5437 mL | 61.0874 mL | 76.3592 mL |
5 mM | 0.6109 mL | 3.0544 mL | 6.1087 mL | 12.2175 mL | 15.2718 mL |
10 mM | 0.3054 mL | 1.5272 mL | 3.0544 mL | 6.1087 mL | 7.6359 mL |
50 mM | 0.0611 mL | 0.3054 mL | 0.6109 mL | 1.2217 mL | 1.5272 mL |
100 mM | 0.0305 mL | 0.1527 mL | 0.3054 mL | 0.6109 mL | 0.7636 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2-Benzoyl-1,3,4,4a,5,8a-hexahydro-6(2H)-isoquinolinone
Catalog No.:BCC8559
CAS No.:52346-14-2
- Alnusone
Catalog No.:BCN8108
CAS No.:52330-11-7
- 6alpha-Chloro-5beta-hydroxywithaferin A
Catalog No.:BCN8007
CAS No.:52329-20-1
- Dimethylcurcumin
Catalog No.:BCN2748
CAS No.:52328-98-0
- Tetramethylcurcumin
Catalog No.:BCN2746
CAS No.:52328-97-9
- p,p-hydroxy-curucumin
Catalog No.:BCC8890
CAS No.:52328-96-8
- Vindorosine
Catalog No.:BCN5668
CAS No.:5231-60-7
- Anisatin
Catalog No.:BCC8118
CAS No.:5230-87-5
- Flavoglaucin
Catalog No.:BCN6398
CAS No.:523-73-9
- Evolitrine
Catalog No.:BCN8350
CAS No.:523-66-0
- Angelicin
Catalog No.:BCN5669
CAS No.:523-50-2
- 4-Amino-2,5-dimethoxy-N-phenylbenzenesulphonamide
Catalog No.:BCC8676
CAS No.:52298-44-9
- Epistephamiersine
Catalog No.:BCN5671
CAS No.:52389-15-8
- Wedelolactone
Catalog No.:BCN5672
CAS No.:524-12-9
- gamma-Fagarine
Catalog No.:BCN5673
CAS No.:524-15-2
- Dauricine
Catalog No.:BCN4977
CAS No.:524-17-4
- Fraxin
Catalog No.:BCN1237
CAS No.:524-30-1
- 2-APB
Catalog No.:BCC6978
CAS No.:524-95-8
- Noricaritin
Catalog No.:BCN5353
CAS No.:5240-95-9
- (R)-DPN
Catalog No.:BCC7939
CAS No.:524047-78-7
- H-Phe-NH2
Catalog No.:BCC3008
CAS No.:5241-58-7
- Boc-D-Trp-OH
Catalog No.:BCC3457
CAS No.:5241-64-5
- Boc-D-Met-OH
Catalog No.:BCC3426
CAS No.:5241-66-7
- Cochlearine
Catalog No.:BCN1929
CAS No.:52418-07-2
Synthesis of the erythrina alkaloid erysotramidine.[Pubmed:25140810]
J Org Chem. 2014 Sep 5;79(17):8481-5.
A concise synthesis of Erysotramidine (an alkaloid belonging to the erythrina family) was achieved starting with an inexpensive phenol and amine derivative. The synthesis is based on oxidative phenol dearomatizations mediated by a hypervalent iodine reagent and includes a novel route to a key indolinone moiety.
Heck cyclization strategy for preparation of erythrinan alkaloids: asymmetric synthesis of unnatural (-)-erysotramidine from L-tartaric acid.[Pubmed:25569446]
J Org Chem. 2015 Feb 6;80(3):1957-63.
With an imide derived from L-tartaric acid as the starting material, ent-Erysotramidine was synthesized for the first time. The synthesis features the use of the enantiopure synthon, prepared in a set of highly stereoselective reactions, including N-acyliminium cyclization, dihydrofuranyl ring formation via silver-catalyzed intramolecular alcohol addition to acetylene, and vinyl ether catalytic hydrogen reduction. The crucial step of the synthesis, assembly of ring A, was achieved by using Heck cyclization of (Z)-iodoolefin.
Efficient formal total synthesis of the erythrina alkaloid (+)-erysotramidine, using a domino process.[Pubmed:19860384]
Org Lett. 2009 Nov 19;11(22):5230-3.
A domino process consisting of an amidation, spirocyclization, and formation of an iminium ion and electrophilic aromatic substitution of a phenylethylamine and a ketoester leads to the spirocyclic skeleton of (+)-Erysotramidine, which can be further transformed into the natural alkaloid.